

Resverlogix Corp. completes C\$87M private placement with Shenzhen Hepalink

Date closed: 12/4/2018

Value: C\$87 million

On December 4, 2017, Resverlogix Corp. (Resverlogix) (TSX:RVX) announced the closing of a private placement of 60,416,667 equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. (Hepalink) at a price of \$1.44 per unit for gross proceeds of \$87 million. Each unit was comprised of one common share and 0.082759 of a common share purchase warrant. Each full warrant is exercisable at a price of \$1.64 per share for a period of four years from the closing of the offering.

Resverlogix, headquartered in Calgary, Alberta, is a biotechnology company, developing an epigenetic drug for the treatment of high-risk cardiovascular disease patients.

BLG represented Resverlogix led by [Lloyd McLellan](#).

For more information, please contact:

Kate Gifford
Borden Ladner Gervais LLP
KGifford@blg.com
416.350.6540



BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[blg.com](https://www.blg.com)

© 2026 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.